YPSILANTI – Integrated Sensing Systems announced that the U.S Patent Office has granted a patent to cover its miniature, wireless, batteryless, implantable hemodynamic sensors to provide advanced chronic patient management.
ISSYS? sensor and anchor are delivered either via a catheter in an outpatient procedure or as an adjunct device during an already-establish procedure such as coronary artery bypass graft. The biocompatible anchor allows the miniature telemetric sensor to be stabilized within the heart and monitor left side of the heart (either left atrium or left ventricle). This is a very difficult task due to the stringent biocompatibility requirements of the left heart.
?The particular targets of ISSYS products are cardiovascular disease, especially congestive heart failure,? said Dr. Nader Najafi, ISSYS CEO. ?This patent further expands the use of these miniature implants with other devices such as pacemakers, implantable cardioverter defibrillators (ICD?s), and drug delivery products. ISSYS implants will facilitate monitoring patients? pressure in ICUs, medical facilities and at home. ISSYS plans to start its cardiovascular clinical studies in 2013. ISSYS? intellectual properties (patents, know how, and trade secrets) cover a wide spectrum including MEMS pressure sensors, wireless systems, delivery and anchoring for a variety of medical applications. In addition, ISSYS expanded its ISO 13485 certified manufacturing facility to produce tens of thousands of these miniature medical implants per year.?
ISSYS developers advanced MEMS technologies for industrial, medical, microfluidic and scientific analytical sensing applications.
